Johnson & Johnson stock holds HSBC Buy rating as shares hover near consensus target

Johnson & Johnson stock (ISIN US4781601046) ended the last completed New York session at USD 267.08 on September 9, 2026, putting the healthcare heavyweight slightly below the average analyst price target of USD 272.83 and in focus for income-oriented and defensive investors.

HSBC sticks with Buy as valuation remains supported

According to MarketScreener on September 10, 2026, HSBC has reaffirmed its Buy rating on Johnson & Johnson while the shares most recently closed at USD 267.08 on the New York Stock Exchange on September 9, 2026.

The same overview from MarketScreener shows an average analyst price target of USD 277.00, implying around 3.7% upside from the latest closing level of USD 267.08 as of September 9, 2026.

For investors, that modest gap between price and target illustrates a market that already prices in much of Johnson & Johnson’s defensive strengths but still leaves some room for capital appreciation if the company continues to execute on its pipeline and MedTech growth plans.

Consensus targets and rating mix stay constructive

Beyond HSBC’s stance, analyst consensus remains supportive. As MarketBeat reported on September 10, 2026, Johnson & Johnson currently carries an average rating of Moderate Buy, with one Strong Buy, eighteen Buy ratings and six Hold recommendations across the Street and a consensus price target of USD 272.83.

According to MarketBeat, UBS Group recently began coverage of Johnson & Johnson with a Buy rating and a USD 320.00 price target, notably above the current consensus and about USD 52.92 above the latest closing price of USD 267.08 on September 9, 2026.

Another institutional positioning update summarized by MarketBeat on September 10, 2026, reiterated the Moderate Buy consensus and the same USD 272.83 average price target, underlining that buy-side interest is supported by both earnings stability and the company’s long dividend track record.

From a risk perspective, commentary around Johnson & Johnson continues to point to litigation exposures and execution risk in MedTech and pharmaceuticals as key watchpoints, even as analysts emphasize the company’s diversified portfolio as a counterbalance.

Dividend profile and recent conference remarks add context

Income investors often look at Johnson & Johnson for its dividend reliability. As highlighted in a dividend-focused comparison in The Globe and Mail on September 9, 2026, Johnson & Johnson pays USD 5.36 per share annually, which translates into a dividend yield of about 1.9% on the recent share price level.The Globe and Mail

That dividend yield, while not the highest in the sector, is backed by a long history of increases, and for many investors it is part of the reason why Johnson & Johnson is considered a staple defensive holding that can help portfolios hold up when broader markets are volatile.

Strategically, Johnson & Johnson has also been highlighting growth opportunities in its MedTech segment. At the Wells Fargo Healthcare Conference, company executives pointed to cardiovascular products as a core area of expansion within MedTech, underlining that this part of the portfolio is expected to contribute meaningfully to growth through 2027.MarketBeat

In a separate transcript of its presentation, Johnson & Johnson reiterated that it expects the markets it serves to expand at roughly mid-single-digit percentages annually between 2022 and 2027, providing a structural tailwind for both its pharmaceutical and MedTech businesses.Seeking Alpha

For shareholders, the combination of a growing underlying market, a steady dividend and supportive analyst coverage is central to the investment case, but the valuation at just a few percent below consensus targets suggests that upside will depend on Johnson & Johnson delivering on its growth guidance and managing legal and regulatory risks effectively.

Stock price, market metrics and investor takeaway

On the price side, Johnson & Johnson stock closed at USD 267.08 on the New York Stock Exchange on September 9, 2026, down 0.76% from the prior session and leaving the shares roughly 2.95% below their level at the start of 2026, according to data compiled in the analyst overview.MarketScreener

That price sits close to the USD 272.83 consensus target cited by MarketBeat on September 10, 2026, and modestly below the higher USD 277.00 average target reported by MarketScreener for the same timeframe, underlining that the stock is trading near, but not above, where much of the Street believes fair value lies.MarketBeat

For retail investors looking at Johnson & Johnson today, the picture is one of a broadly liked, income-paying healthcare stock where analyst targets offer modest upside from current levels and where future performance will hinge on consistent execution in MedTech and pharmaceuticals rather than a re-rating story.

More news and analyses on Johnson & Johnson stock